Drug-resistant TB and HIV in resource-limited settings: What TB/HIV programmes can learn from each other

Tropical Medicine and International Health

Volumn 13, Issue 9, 2008, Pages 1204-1207

  Colebunders, R ^a,b   Worodria, W ^c   Jones Lopez E ^d   Joloba, M ^c   Apers, L ^a   Ellner, J ^d  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c MAKERERE UNIVERSITY   (Uganda)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Extensive resistant tuberculosis; Multidrug resistant HIV infection; Multidrug resistant tuberculosis; Resource limited settings

Indexed keywords

AMIKACIN; ANTIRETROVIRUS AGENT; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

DISEASE CONTROL; DRUG RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS; RESOURCE SCARCITY; TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; BIOLOGICAL MONITORING; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG QUALITY; DRUG TREATMENT FAILURE; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LETHAL DOSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; SHORT SURVEY; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS INHIBITION; VIRUS LOAD;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIMALARIALS; BIOMEDICAL RESEARCH; DEVELOPING COUNTRIES; DISEASE OUTBREAKS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HUMANS; PROGRAM EVALUATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 50049118456     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2008.02127.x     Document Type: Short Survey

References (23)

1. Baggaley RF, Garnett GP Ferguson NM (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Medicine 3, e124.
2. Clinton Foundation (2008) Latest antiretroviral price list. http://www.clintonfoundation.org/pdf/chai-arv-price-list-050807.pdf (accessed 15 March 2008).
3. Gilks CF, Crowley S, Ekpini R et al. (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368, 505 510.
4. Goldman RC, Plumley KV Laughon BE (2007) The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infectious Disorder Drug Targets 7, 73 91.
5. Gupta R, Cegielski JP, Espinal MA et al. (2002) Increasing transparency in partnerships for health - introducing the Green Light Committee. Tropical Medicine and International Health 7, 970 976.
6. Kamwi R, Kenyon T Newton G (2006) PEPFAR and HIV prevention in Africa. Lancet 367, 1978 1979.
7. Kazatchkine M (2007) The global fund expands its role. Bulletin of the World Health Organization 85, 742 743.
8. Matteelli A, Migliori GB, Cirillo D, Centis R, Girard E Raviglion M (2007) Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Review of Anti-Infective Therapy 5, 857 871.
9. Mitnick CD, Castro KG, Harrington M, Sacks LV Burman W (2007) Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Medicine 4, e292.
10. Monno L, Punzi G, Brindicci G et al. (2007) A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient. AIDS Research and Human Retroviruses 23, 1293 1295.
11. Mukherjee JS, Rich ML, Socci AR et al. (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363, 474 481.
12. Nathanson E, Lambregts-van Weezenbeek C, Rich ML et al. (2006) Multidrug-resistant tuberculosis management in resource-limited settings. Emerging Infectious Diseases 12, 1389 1397.
13. Padayatchi N Friedland G (2007) Managing multiple and extensively drug-resistant tuberculosis and HIV. Expert Opinion on Pharmacotherapy 8, 1035 1037.
14. Renaud-Théry F, Nguimfack BD, Vitoria M et al. (2007) Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 21 (Suppl. 4 S89 95.
15. Sungkanuparph S, Eampokalap B, Chottanapund S, Thongyen S Manosuthi W (2007) Impact of drug-resistant tuberculosis on the survival of HIV-infected patients. International Journal of Tuberculosis and Lung Disease 11, 325 330.
16. Toni T, Masquelier B Minga A (2007) HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006. AIDS Research and Human Retroviruses 23, 1155 1160.
17. Vekemans M, John L Colebunders R (2007) When to switch for antiretroviral treatment failure in resource-limited settings? AIDS 21, 1205 1206.
18. WHO (2007a) Global Tuberculosis Control. Surveillance, Planning, Financing WHO/HTM/TB/2007.376) WHO, Geneva. http://www.who.int/tb/publications/ global_report/en/.
19. WHO (2007b) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. http://www.who.int/hiv/mediacentre/ universal_access_progress_report_en.pdf.
20. WHO (2008a) Anti-tuberculosis Drug resistance in the World. Report No.4 WHO/HTM/TB/2008.394) WHO, Geneva. http://www.who.int/tb/publications/2008/ drs_report4_26feb08.pdf.
21. WHO (2008b) Guidelines for Surveillance of Drug Resistance in Tuberculosis WHO/TB/94.178) WHO, Geneva.
22. WHO (2008c) The green light committee (GLC) initiative. http://www.who.int/tb/challenges/mdr/greenlightcommittee/en/index.html.
23. WHO/UNAIDS (2006) Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. http://www.who.int/bulletin/ volumes/84/7/editorial10706html/en/.